Please use this identifier to cite or link to this item:
Title: Mycophenolate mofetil as an adjuvant drug for the treatment of pemphigus vulgaris and pemphigus foliaceus
Authors: LOUREIRO, Vivian BarziMARUTA, CelinaSANTI, Claudia GiuliAOKI, Valeria
Citation: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, v.66, n.4, suppl.S, p.AB105-AB105, 2012
Abstract: Background: Pemphigus is a rare autoimunne bullous disease, characterized by blisters and erosions of the skin and/or mucous membranes. Its potentially life-threatening condition has been modified after the introduction of systemic corticosteroids. However, the long-term use of corticosteroids may lead to serious adverse effects. Mycophenolate mofetil has been used as a corticosteroid-sparing agent in the treatment of pemphigus. Objectives: To evaluate the effectiveness and safety of mycophenolate mofetil as adjuvant therapy in patients with pemphigus vulgaris and foliaceus. Methods: The study analyzed 23 patients diagnosed as pemphigus vulgaris (N = 17) or pemphigus foliaceus (N = 6), who had failed to previous treatments or experienced significant adverse effects with azathioprine, and were treated with mycophenolate mofetil. We also performed indirect immunofluorescence before andafter introduction of Mycophenolate Mofetil. Results: Remission wasachieved in 20 out of 23 patients (87%), and was characterized as follows: complete remission off therapy (N = 2), complete remission on minimal therapy (N = 6), partial remission on therapy (N = 6) and partial remission on minimal therapy (N = 6). Failure occurred in three out of 23 patients. Mycophenolate mofetil was well tolerated, once 20 out of 23 patients had no adverse effects. Conclusion: Mycophenolate mofetil has been demonstrated to be an effective and safe adjuvant drug in the treatment of pemphigus vulgaris and foliaceus, who had failed to previous treatments or experienced significant adverse effects with azathioprine.
Appears in Collections:

Comunicações em Eventos - FM/MDT
Departamento de Dermatologia - FM/MDT

Comunicações em Eventos - HC/ICHC
Instituto Central - HC/ICHC

Comunicações em Eventos - LIM/56
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.